4/4
08:18 am
amgn
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts [Yahoo! Finance]
Medium
Report
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts [Yahoo! Finance]
4/4
07:27 am
amgn
RFK Jr. May Want To Ban Prescription Drug Ads, But Can He? [Forbes]
Medium
Report
RFK Jr. May Want To Ban Prescription Drug Ads, But Can He? [Forbes]
4/3
04:57 pm
amgn
Global Cancer Research Community Gathers to Share Breakthroughs at The Mark Foundation's 2025 Scientific Symposium [Yahoo! Finance]
Medium
Report
Global Cancer Research Community Gathers to Share Breakthroughs at The Mark Foundation's 2025 Scientific Symposium [Yahoo! Finance]
4/3
03:35 pm
amgn
UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE
Low
Report
UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE
4/3
06:52 am
amgn
Got $5,000? These 3 Nasdaq Stocks Are Dirt Cheap Buys Right Now [Yahoo! Finance]
Low
Report
Got $5,000? These 3 Nasdaq Stocks Are Dirt Cheap Buys Right Now [Yahoo! Finance]
3/30
03:58 pm
amgn
One dose of experimental drug nearly wipes out stealthy cholesterol in 'remarkable' trial [MSNBC.com]
Low
Report
One dose of experimental drug nearly wipes out stealthy cholesterol in 'remarkable' trial [MSNBC.com]
3/29
02:07 am
amgn
Amgen Inc. (NASDAQ: AMGN) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Low
Report
Amgen Inc. (NASDAQ: AMGN) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
3/24
07:10 pm
amgn
Amgen (AMGN) Stock Drops Despite Market Gains: Important Facts to Note [Yahoo! Finance]
Low
Report
Amgen (AMGN) Stock Drops Despite Market Gains: Important Facts to Note [Yahoo! Finance]
3/23
01:58 pm
amgn
Is Amgen Inc. (AMGN) The Best Healthcare Dividend Stock to Invest in? [Yahoo! Finance]
Low
Report
Is Amgen Inc. (AMGN) The Best Healthcare Dividend Stock to Invest in? [Yahoo! Finance]
3/18
07:35 am
amgn
What Companies Can Do To Address Prescription Drug Market Manipulation [Forbes]
Low
Report
What Companies Can Do To Address Prescription Drug Market Manipulation [Forbes]
3/17
08:08 pm
amgn
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider [Yahoo! Finance]
Low
Report
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider [Yahoo! Finance]
3/13
12:19 pm
amgn
Is Amgen Inc. (AMGN) the Best Pharma Stock to Buy According to Hedge Funds? [Yahoo! Finance]
Low
Report
Is Amgen Inc. (AMGN) the Best Pharma Stock to Buy According to Hedge Funds? [Yahoo! Finance]
3/13
09:00 am
amgn
UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS
Low
Report
UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS
3/12
09:07 am
amgn
Bispecific Antibody Market Opportunity, Drug Dosage, Patent, Price, Sales & Clinical Trials Insight 2030: New Report Highlights 600+ Bispecific Antibodies in Clinical Trials Worldwide [Yahoo! Finance]
Low
Report
Bispecific Antibody Market Opportunity, Drug Dosage, Patent, Price, Sales & Clinical Trials Insight 2030: New Report Highlights 600+ Bispecific Antibodies in Clinical Trials Worldwide [Yahoo! Finance]
3/11
11:08 pm
amgn
AMGN- A Big Pharma Name Bucking the Bearish Market Trend [Yahoo! Finance]
Low
Report
AMGN- A Big Pharma Name Bucking the Bearish Market Trend [Yahoo! Finance]
3/10
03:31 pm
amgn
Amgen Inc. (NASDAQ: AMGN) was given a new $294.00 price target on by analysts at Johnson Rice.
Low
Report
Amgen Inc. (NASDAQ: AMGN) was given a new $294.00 price target on by analysts at Johnson Rice.
3/8
06:13 am
amgn
2 Dividend Stocks to Buy for a Lifetime of Passive Income [Yahoo! Finance]
Low
Report
2 Dividend Stocks to Buy for a Lifetime of Passive Income [Yahoo! Finance]
3/8
06:00 am
amgn
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Low
Report
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
3/8
06:00 am
amgn
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Low
Report
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
3/7
05:49 am
amgn
Cerebral Infarction Treatment Market Analysis Report 2025-2030: Hospital Pharmacies Capture 63.6% of Cerebral Infarction Treatment Distribution in 2024 [Yahoo! Finance]
Medium
Report
Cerebral Infarction Treatment Market Analysis Report 2025-2030: Hospital Pharmacies Capture 63.6% of Cerebral Infarction Treatment Distribution in 2024 [Yahoo! Finance]
3/5
09:00 pm
amgn
AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Low
Report
AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
3/5
01:19 pm
amgn
Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at Bank of America Co. from $275.00 to $294.00. They now have an "underperform" rating on the stock.
Low
Report
Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at Bank of America Co. from $275.00 to $294.00. They now have an "underperform" rating on the stock.
3/5
10:40 am
amgn
Amgen begins late-stage trials for obesity therapy [Seeking Alpha]
Low
Report
Amgen begins late-stage trials for obesity therapy [Seeking Alpha]
3/4
04:54 pm
amgn
AMGEN ANNOUNCES 2025 SECOND QUARTER DIVIDEND
Low
Report
AMGEN ANNOUNCES 2025 SECOND QUARTER DIVIDEND
3/1
05:30 pm
amgn
POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Low
Report
POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS